Exploring Polypharmacology Using a ROCS-Based Target Fishing Approach
暂无分享,去创建一个
Anders Wallqvist | Narender Singh | Mohamed Diwan M. AbdulHameed | Hongmao Sun | Gregory J. Tawa | Sidhartha Chaudhury | A. Wallqvist | Hongmao Sun | S. Chaudhury | M. AbdulHameed | Narender Singh | G. Tawa | Sidhartha Chaudhury
[1] G Wolber,et al. Enhancing drug discovery through in silico screening: strategies to increase true positives retrieval rates. , 2008, Current medicinal chemistry.
[2] J. Mestres,et al. A ligand-based approach to mining the chemogenomic space of drugs. , 2008, Combinatorial chemistry & high throughput screening.
[3] Didier Rognan,et al. Structure‐Based Approaches to Target Fishing and Ligand Profiling , 2010, Molecular informatics.
[4] Susumu Goto,et al. KEGG for representation and analysis of molecular networks involving diseases and drugs , 2009, Nucleic Acids Res..
[5] Christine Humblet,et al. Computation of 3D queries for ROCS based virtual screens , 2009, J. Comput. Aided Mol. Des..
[6] A. Bender,et al. In silico target fishing: Predicting biological targets from chemical structure , 2006 .
[7] J. Irwin,et al. Benchmarking sets for molecular docking. , 2006, Journal of medicinal chemistry.
[8] G. Klebe,et al. Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-selective celecoxib: new pharmacological opportunities due to related binding site recognition. , 2004, Journal of medicinal chemistry.
[9] Hugo A Katus,et al. hERG: protein trafficking and potential for therapy and drug side effects. , 2010, Current opinion in drug discovery & development.
[10] David S. Wishart,et al. DrugBank: a knowledgebase for drugs, drug actions and drug targets , 2007, Nucleic Acids Res..
[11] John R Cashman,et al. Dual inhibitors of phosphodiesterase-4 and serotonin reuptake. , 2009, Journal of medicinal chemistry.
[12] Z. Deng,et al. Bridging chemical and biological space: "target fishing" using 2D and 3D molecular descriptors. , 2006, Journal of medicinal chemistry.
[13] Lin He,et al. SePreSA: a server for the prediction of populations susceptible to serious adverse drug reactions implementing the methodology of a chemical–protein interactome , 2009, Nucleic Acids Res..
[14] H. L. Morgan. The Generation of a Unique Machine Description for Chemical Structures-A Technique Developed at Chemical Abstracts Service. , 1965 .
[15] T. Ashburn,et al. Drug repositioning: identifying and developing new uses for existing drugs , 2004, Nature Reviews Drug Discovery.
[16] David Rogers,et al. Cheminformatics analysis and learning in a data pipelining environment , 2006, Molecular Diversity.
[17] A. Hopkins. Network pharmacology: the next paradigm in drug discovery. , 2008, Nature chemical biology.
[18] J. Palacios,et al. Anticholinergic effects of desloratadine, the major metabolite of loratadine, in rabbit and guinea-pig iris smooth muscle. , 1999, European journal of pharmacology.
[19] Michael J. Keiser,et al. Predicting new molecular targets for known drugs , 2009, Nature.
[20] William L. Jorgensen,et al. Journal of Chemical Information and Modeling , 2005, J. Chem. Inf. Model..
[21] Michael J. Keiser,et al. Relating protein pharmacology by ligand chemistry , 2007, Nature Biotechnology.
[22] Liwei Li,et al. BioDrugScreen: a computational drug design resource for ranking molecules docked to the human proteome , 2009, Nucleic Acids Res..
[23] Brian K. Shoichet,et al. Virtual screening of chemical libraries , 2004, Nature.
[24] David B Jackson,et al. Drug profiling: knowing where it hits. , 2010, Drug discovery today.
[25] Peter Willett,et al. Similarity-based virtual screening using 2D fingerprints. , 2006, Drug discovery today.
[26] I. Kola,et al. Can the pharmaceutical industry reduce attrition rates? , 2004, Nature Reviews Drug Discovery.
[27] I. van Wijngaarden,et al. 2-Phenylpyrroles as conformationally restricted benzamide analogues. A new class of potential antipsychotics. 1. , 1987, Journal of medicinal chemistry.
[28] Nanda Ghoshal,et al. Hybrid Structure-Based Virtual Screening Protocol for the Identification of Novel BACE1 Inhibitors , 2009, J. Chem. Inf. Model..
[29] Ajay N. Jain,et al. Robust ligand-based modeling of the biological targets of known drugs. , 2006, Journal of medicinal chemistry.
[30] C. Laggner,et al. Why drugs fail--a study on side effects in new chemical entities. , 2005, Current pharmaceutical design.
[31] Jérôme Hert,et al. Comparison of Fingerprint-Based Methods for Virtual Screening Using Multiple Bioactive Reference Structures , 2004, J. Chem. Inf. Model..
[32] K. Fan,et al. Molecular-modeling based design, synthesis, and activity of substituted piperidines as gamma-secretase inhibitors. , 2005, Bioorganic & medicinal chemistry letters.
[33] J Edelson,et al. Interactions of chlorphenesin and divalent metal ions with phosphodiesterase. , 1976, Archives internationales de pharmacodynamie et de therapie.
[34] Katya Tsaioun,et al. ADDME – Avoiding Drug Development Mistakes Early: central nervous system drug discovery perspective , 2009, BMC neurology.
[35] A. Cavalli,et al. Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K(+) channel blockers. , 2002, Journal of medicinal chemistry.
[36] J. Jenkins,et al. Prediction of Biological Targets for Compounds Using Multiple‐Category Bayesian Models Trained on Chemogenomics Databases. , 2006 .
[37] William Loging,et al. High-throughput electronic biology: mining information for drug discovery , 2007, Nature Reviews Drug Discovery.
[38] Xiaozhou Yao,et al. Propranolol inhibits the human ether-a-go-go-related gene potassium channels. , 2005, European journal of pharmacology.
[39] John P. Overington,et al. How many drug targets are there? , 2006, Nature Reviews Drug Discovery.
[40] E. van Luijtelaar,et al. Rat models of genetic absence epilepsy: what do EEG spike-wave discharges tell us about drug effects? , 2002, Methods and findings in experimental and clinical pharmacology.
[41] Scott Boyer,et al. Ligand-Based Approach to In Silico Pharmacology: Nuclear Receptor Profiling , 2006, J. Chem. Inf. Model..
[42] Michael C Sanguinetti,et al. Predicting drug-hERG channel interactions that cause acquired long QT syndrome. , 2005, Trends in pharmacological sciences.
[43] Peter Imming,et al. Drugs, their targets and the nature and number of drug targets , 2007, Nature Reviews Drug Discovery.
[44] D. Wong,et al. Fluoxetine and two other serotonin uptake inhibitors without affinity for neuronal receptors. , 1983, Biochemical pharmacology.
[45] C. Singer,et al. Rimantadine in Parkinson's disease patients experiencing peripheral adverse effects from amantadine: Report of a case series , 2005, Movement disorders : official journal of the Movement Disorder Society.
[46] Y.Z. Chen,et al. Ligand–protein inverse docking and its potential use in the computer search of protein targets of a small molecule , 2001, Proteins.
[47] J. A. Grant,et al. A shape-based 3-D scaffold hopping method and its application to a bacterial protein-protein interaction. , 2005, Journal of medicinal chemistry.
[48] C. Humblet,et al. Modeling G protein‐coupled receptors for structure‐based drug discovery using low‐frequency normal modes for refinement of homology models: Application to H3 antagonists , 2010, Proteins.
[49] Scott Boyer,et al. Ligand-Based Approach to in Silico Pharmacology: Nuclear Receptor Profiling. , 2007 .
[50] Xiaomin Luo,et al. TarFisDock: a web server for identifying drug targets with docking approach , 2006, Nucleic Acids Res..